Teladoc Health Logo
US87918A1051
A14VPK
TDOC

Teladoc Health

Loading quotes...

Forecast

The analysts' average price target is €8.08 (+50.19%). The median is €8.18 (+52.04%).

Buy
  15
Hold
  27
Sell
  0

  • Teladoc Health appoints Michael Grasher as chief financial officer

    Teladoc Health has appointed Michael Grasher as CFO, effective immediately. Grasher has more than 30 years of experience in the insurance and financial services sector, including over 12 years in CFO roles at companies such as IFG Companies, Fortegra and AMERISAFE, and he also spent many years in equity research. » More on de.investing.com


  • Teladoc Health appoints Mark V. Anquillare to the board of directors

    Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » More on de.investing.com


  • Teladoc reports revenue decline and cuts annual forecast – stock falls sharply

    Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, Teladoc Health has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Teladoc Health had revenue of €531.8M and net profit of -€34.09M
(EUR) June 2026
YoY
Revenue 531.8M 0.81%
Gross profit 545.08M 45.56%
Net profit -34.09M 23.03%
EBITDA -109.12M 4,907.89%

Fundamentals

Metric Value
Market capitalization
€982.57M
Number of shares
181.68M
52-week high/low
€8.51 - €3.79
Dividends No
Beta
2.13
P/E ratio
-6.34
PEG ratio
-0.38
P/B ratio
0.86
P/S ratio
0.46

Company profile

Teladoc Health, Inc. bietet virtuelle Gesundheitsdienste in den Vereinigten Staaten und international an. Das Unternehmen bietet ein Portfolio von Dienstleistungen und Lösungen für nicht dringende, episodische, chronische und komplizierte medizinische Erkrankungen, einschließlich Diabetes, Bluthochdruck, chronische Nierenerkrankungen, Krebs, Herzinsuffizienz und psychische Erkrankungen. Das Unternehmen bietet eine Reihe von Programmen und Dienstleistungen an, darunter Lösungen für die telemedizinische Grund- und Spezialversorgung, das Management chronischer Erkrankungen, medizinische Expertendienste, Lösungen für psychische Erkrankungen sowie Plattform- und Programmdienste. Das Unternehmen bedient Arbeitgeber, Gesundheitspläne, Krankenhäuser und Gesundheitssysteme, Versicherungs- und Finanzdienstleistungsunternehmen sowie Einzelmitglieder. Es bietet seine Produkte und Dienstleistungen unter den Marken Teladoc, Livongo und BetterHelp an. Das Unternehmen war früher als Teladoc, Inc. bekannt und änderte im August 2018 seinen Namen in Teladoc Health, Inc. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Purchase, New York.

Name
Teladoc Health
CEO
Charles Divita
Headquarters New York, ny
USA
Website
Sector
Health Care
Industry
Health Care Providers & Services
IPO
06/30/2015
Employees 5,124

Ticker symbols

Exchange Symbol
NYSE
TDOC
London Stock Exchange
0LDR.L
XETRA
4LL.F
Frankfurt
4LL.F
DĂĽsseldorf
4LL.DU
London
0LDR.L
SIX
4LL.SW
MĂĽnchen
4LL.MU

Discover assets

Shareholders of Teladoc Health also invest in the following assets

🍪

Parqet  uses cookies. Learn more